Key result
Exposure to blood products in hemophiliacs was associated with a 58.4% HAV prevalence at entry and a 7.8% seroconversion rate among susceptible patients.
Why the study?
Does treatment with blood products and clotting factor concentrates increase the risk of HAV seroconversion in hemophiliacs?
Cohort (n=339)
Does treatment with blood products and clotting factor concentrates increase the risk of HAV seroconversion in hemophiliacs?
Hemophiliacs have a high baseline prevalence of HAV, and seroconversion can occur following administration of intravenous immune globulin and other blood products.
Answers are grounded in this paper and cite their sources.
May warrant HAV vigilance with blood products in hemophiliacs; leaves open causal risk from observational data.
To address the question of HAV prevalence and seroconversion in relation to clotting factor concentrates, we assayed an early serum for 339 hemophiliacs followed every 6 months by the Transfusion Safety Study in the period from mid-1985 until mid-1992. We found 58.4% positive around entry, with an age-specific prevalence that did not vary with age. In comparison to rates for anti-HIV-negative blood donors, they were significantly higher. Based on testing of subsequent sera, 11 hemophiliacs (7.8% of 141 susceptibles) changed their anti-HAV status from negative to positive. In 9 instances, positivity immediately followed the first dose of intravenous immune globulin. A possible seroconversion followed treatment with blood components, and a possible seroconversion followed intermediate-purity, solvent/detergent(SD)-treated factor VIII concentrate. Neither of these 2 patients was anti-HAV IgM positive, so that passively transferred antibody is possible. The high prevalence among hemophiliacs at entry must be further investigated by determining the expected background rate in a US population similar to the hemophilia patients, and by comparing anti-HAV prevalence associated with SD-treated and heat-inactivated concentrates.
No takes yet. Share an insight, caveat, or question.
Mosley et al. (1994) conducted a cohort in Hemophilia (n=339). Clotting factor concentrates and blood products vs. Anti-HIV-negative blood donors was evaluated on HAV seroconversion. Exposure to blood products in hemophiliacs was associated with a 58.4% HAV prevalence at entry and a 7.8% seroconversion rate among susceptible patients.
Synapse has enriched 10 related papers. Consider them for comparative context: